{"id":1892,"date":"2024-06-22T13:12:39","date_gmt":"2024-06-22T13:12:39","guid":{"rendered":"https:\/\/myneuronews.com\/?p=1892"},"modified":"2025-04-27T10:52:25","modified_gmt":"2025-04-27T10:52:25","slug":"blood-biomarkers-in-mtbi","status":"publish","type":"post","link":"https:\/\/beyondtheimpact.net\/?p=1892","title":{"rendered":"Blood biomarkers in mTBI"},"content":{"rendered":"\n

The relationship between blood biomarkers and clinical recovery in concussion, particularly mild traumatic brain injury (mTBI), is a complex and evolving field. Blood biomarkers have shown promise in aiding diagnosis, prognosis, and monitoring recovery, but several challenges and limitations remain.<\/p>\n\n\n\n

Key Blood Biomarkers<\/h3>\n\n\n\n
    \n
  1. S100B<\/strong>: This protein is widely studied and included in Scandinavian and French guidelines to reduce unnecessary CT scans in mTBI patients. It is effective when measured within a few hours post-injury but has limitations due to its rapid half-life and lack of neurospecificity[4].<\/li>\n\n\n\n
  2. Glial Fibrillary Acidic Protein (GFAP)<\/strong>: GFAP is useful in detecting intracranial injuries and has been approved by the FDA for this purpose. It is particularly valuable when combined with UCH-L1, as it can be measured up to 12 hours post-injury, providing a broader diagnostic window[4][5].<\/li>\n\n\n\n
  3. Ubiquitin Carboxy-terminal Hydrolase L1 (UCH-L1)<\/strong>: This biomarker, also FDA-approved, complements GFAP in diagnosing mTBI. It helps in identifying patients who may need further imaging and monitoring[4][5].<\/li>\n\n\n\n
  4. Neurofilament Light Chain (Nf-L)<\/strong>: Nf-L levels increase following a concussion and are associated with axonal damage. However, their correlation with clinical recovery and symptom severity is not well-established[1][3].<\/li>\n\n\n\n
  5. Tau<\/strong>: Tau protein levels tend to decrease after a concussion. Like Nf-L, its relationship with clinical recovery is not definitive, but it provides insights into the extent of neuronal damage[1][3].<\/li>\n<\/ol>\n\n\n\n

    Clinical Utility and Limitations<\/h3>\n\n\n\n
      \n
    • Diagnosis and Prognosis<\/strong>: Blood biomarkers like GFAP and UCH-L1 improve diagnostic accuracy and help stratify patients based on the severity of their injury. They are particularly useful in distinguishing between patients who need CT scans and those who do not, thereby reducing unnecessary imaging[4][5].<\/li>\n\n\n\n
    • Monitoring Recovery<\/strong>: Biomarkers can track the biological processes underlying recovery. For instance, changes in biomarker levels over time can indicate the progression of recovery. However, the direct correlation between biomarker levels and clinical recovery milestones, such as symptom resolution, is still under investigation[1][3].<\/li>\n<\/ul>\n\n\n\n

      Unresolved Issues<\/h3>\n\n\n\n

      Despite their potential, several unresolved issues limit the widespread clinical adoption of blood biomarkers in concussion management:<\/p>\n\n\n\n

        \n
      1. Pathways and Kinetics<\/strong>: The exact pathways through which biomarkers enter the blood and their kinetics are not fully understood. This lack of knowledge complicates the interpretation of biomarker levels[1][3].<\/li>\n\n\n\n
      2. Optimal Sampling Times<\/strong>: The best times to sample blood for these biomarkers post-injury are not well-established, which can affect their reliability and utility in clinical practice[1][3].<\/li>\n\n\n\n
      3. Correlation with Clinical Measures<\/strong>: There is limited evidence that blood biomarker levels correlate strongly with clinical measures of mTBI severity or recovery. This weak correlation suggests that while biomarkers can provide valuable information, they should be used alongside other clinical assessments[1][3].<\/li>\n<\/ol>\n\n\n\n

        Future Directions<\/h3>\n\n\n\n
          \n
        • Standardization and Validation<\/strong>: More research is needed to standardize the use of biomarkers and validate their effectiveness across different populations and settings.<\/li>\n\n\n\n
        • Pediatric Considerations<\/strong>: Specific studies focusing on pediatric populations are necessary, as biomarkers validated in adults may not be appropriate for children[4].<\/li>\n\n\n\n
        • New Biomarkers<\/strong>: Ongoing research aims to identify new biomarkers and refine existing ones to improve their diagnostic and prognostic capabilities[4].<\/li>\n<\/ul>\n\n\n\n

          In summary, while blood biomarkers offer significant promise for enhancing the management of concussions, particularly in diagnosing and monitoring recovery, further research is needed to address the unresolved issues and validate their clinical utility comprehensively.<\/p>\n\n\n\n

          Citations:
          [1] https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-021-00325-5
          [2] https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2772529423010238
          [3] https:\/\/pubmed.ncbi.nlm.nih.gov\/34530937\/
          [4] https:\/\/academic.oup.com\/clinchem\/advance-article\/doi\/10.1093\/clinchem\/hvae049\/7657608?searchresult=1
          [5] https:\/\/www.neurology.org\/doi\/10.1212\/WNL.0000000000207881<\/p>\n","protected":false},"excerpt":{"rendered":"

          Several studies have demonstrated that elevated levels of S100B, GFAP, UCH-L1, and NFL correlate with the presence and severity of mTBI. S100B, a marker of astrocytic damage, has been shown to have high sensitivity but moderate specificity for mTBI. GFAP, another astrocytic marker, exhibits higher specificity and is particularly useful in differentiating mTBI from other conditions. UCH-L1, a marker of neuronal cell body injury, and NFL, indicative of axonal damage, both show promise in reflecting the extent of neuronal injury and predicting recovery outcomes. Additionally, combinations of these biomarkers may enhance diagnostic accuracy and provide more comprehensive insights into the injury mechanisms and prognosis.
          \nThe use of blood biomarkers in mTBI offers several advantages, including non-invasiveness, rapid turnaround time, and the potential for point-of-care testing. However, challenges such as variability in biomarker levels due to individual differences, the influence of extracranial injuries, and the need for standardized protocols must be addressed. Further research is required to validate these biomarkers in larger, diverse populations and to establish clear clinical guidelines for their use.<\/p>\n","protected":false},"author":2,"featured_media":1893,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[24,15],"tags":[196,197,19,198,199,200,201],"class_list":["post-1892","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biomarkers","category-traumatic-brain-injury","tag-blood-biomarkers","tag-gfap","tag-mtbi","tag-nf-l","tag-s100b","tag-tau","tag-uch-l1"],"yoast_head":"\nBlood biomarkers in mTBI - Beyond the Impact<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/beyondtheimpact.net\/?p=1892\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Blood biomarkers in mTBI - Beyond the Impact\" \/>\n<meta property=\"og:description\" content=\"Several studies have demonstrated that elevated levels of S100B, GFAP, UCH-L1, and NFL correlate with the presence and severity of mTBI. S100B, a marker of astrocytic damage, has been shown to have high sensitivity but moderate specificity for mTBI. GFAP, another astrocytic marker, exhibits higher specificity and is particularly useful in differentiating mTBI from other conditions. UCH-L1, a marker of neuronal cell body injury, and NFL, indicative of axonal damage, both show promise in reflecting the extent of neuronal injury and predicting recovery outcomes. Additionally, combinations of these biomarkers may enhance diagnostic accuracy and provide more comprehensive insights into the injury mechanisms and prognosis. The use of blood biomarkers in mTBI offers several advantages, including non-invasiveness, rapid turnaround time, and the potential for point-of-care testing. However, challenges such as variability in biomarker levels due to individual differences, the influence of extracranial injuries, and the need for standardized protocols must be addressed. Further research is required to validate these biomarkers in larger, diverse populations and to establish clear clinical guidelines for their use.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/beyondtheimpact.net\/?p=1892\" \/>\n<meta property=\"og:site_name\" content=\"Beyond the Impact\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-22T13:12:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-27T10:52:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/beyondtheimpact.net\/wp-content\/uploads\/2024\/06\/x6pfyknb-1024x585.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"585\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Dr Ioannis Mavroudis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr Ioannis Mavroudis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/beyondtheimpact.net\/?p=1892#article\",\"isPartOf\":{\"@id\":\"https:\/\/beyondtheimpact.net\/?p=1892\"},\"author\":{\"name\":\"Dr Ioannis Mavroudis\",\"@id\":\"https:\/\/beyondtheimpact.net\/#\/schema\/person\/1ae68bbf93b4c1d993f388d942a93c4b\"},\"headline\":\"Blood biomarkers in mTBI\",\"datePublished\":\"2024-06-22T13:12:39+00:00\",\"dateModified\":\"2025-04-27T10:52:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/beyondtheimpact.net\/?p=1892\"},\"wordCount\":565,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/beyondtheimpact.net\/#organization\"},\"image\":{\"@id\":\"https:\/\/beyondtheimpact.net\/?p=1892#primaryimage\"},\"thumbnailUrl\":\"https:\/\/beyondtheimpact.net\/wp-content\/uploads\/2024\/06\/x6pfyknb.png\",\"keywords\":[\"blood biomarkers\",\"GFAP\",\"mTBI\",\"Nf-L\",\"s100b\",\"Tau\",\"UCH-L1\"],\"articleSection\":[\"Biomarkers\",\"Traumatic brain injury\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/beyondtheimpact.net\/?p=1892#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/beyondtheimpact.net\/?p=1892\",\"url\":\"https:\/\/beyondtheimpact.net\/?p=1892\",\"name\":\"Blood biomarkers in mTBI - Beyond the Impact\",\"isPartOf\":{\"@id\":\"https:\/\/beyondtheimpact.net\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/beyondtheimpact.net\/?p=1892#primaryimage\"},\"image\":{\"@id\":\"https:\/\/beyondtheimpact.net\/?p=1892#primaryimage\"},\"thumbnailUrl\":\"https:\/\/beyondtheimpact.net\/wp-content\/uploads\/2024\/06\/x6pfyknb.png\",\"datePublished\":\"2024-06-22T13:12:39+00:00\",\"dateModified\":\"2025-04-27T10:52:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/beyondtheimpact.net\/?p=1892#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/beyondtheimpact.net\/?p=1892\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/beyondtheimpact.net\/?p=1892#primaryimage\",\"url\":\"https:\/\/beyondtheimpact.net\/wp-content\/uploads\/2024\/06\/x6pfyknb.png\",\"contentUrl\":\"https:\/\/beyondtheimpact.net\/wp-content\/uploads\/2024\/06\/x6pfyknb.png\",\"width\":1792,\"height\":1024},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/beyondtheimpact.net\/?p=1892#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/beyondtheimpact.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Blood biomarkers in mTBI\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/beyondtheimpact.net\/#website\",\"url\":\"https:\/\/beyondtheimpact.net\/\",\"name\":\"BeyondTheImpact\",\"description\":\"Concussion, FND and Neuroscience\",\"publisher\":{\"@id\":\"https:\/\/beyondtheimpact.net\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/beyondtheimpact.net\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/beyondtheimpact.net\/#organization\",\"name\":\"Beyond the Impact\",\"url\":\"https:\/\/beyondtheimpact.net\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/beyondtheimpact.net\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/beyondtheimpact.net\/wp-content\/uploads\/2025\/04\/955D378D-9439-4958-AA9D-866B66877DCB-1.png\",\"contentUrl\":\"https:\/\/beyondtheimpact.net\/wp-content\/uploads\/2025\/04\/955D378D-9439-4958-AA9D-866B66877DCB-1.png\",\"width\":1024,\"height\":1024,\"caption\":\"Beyond the Impact\"},\"image\":{\"@id\":\"https:\/\/beyondtheimpact.net\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/beyondtheimpact.net\/#\/schema\/person\/1ae68bbf93b4c1d993f388d942a93c4b\",\"name\":\"Dr Ioannis Mavroudis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/beyondtheimpact.net\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/41234bd7f101fbc35534c2cb229c8f7ce061ccbc2ba5bfa19c9dca8b22e28139?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/41234bd7f101fbc35534c2cb229c8f7ce061ccbc2ba5bfa19c9dca8b22e28139?s=96&d=mm&r=g\",\"caption\":\"Dr Ioannis Mavroudis\"},\"url\":\"https:\/\/beyondtheimpact.net\/?author=2\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Blood biomarkers in mTBI - Beyond the Impact","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/beyondtheimpact.net\/?p=1892","og_locale":"en_US","og_type":"article","og_title":"Blood biomarkers in mTBI - Beyond the Impact","og_description":"Several studies have demonstrated that elevated levels of S100B, GFAP, UCH-L1, and NFL correlate with the presence and severity of mTBI. S100B, a marker of astrocytic damage, has been shown to have high sensitivity but moderate specificity for mTBI. GFAP, another astrocytic marker, exhibits higher specificity and is particularly useful in differentiating mTBI from other conditions. UCH-L1, a marker of neuronal cell body injury, and NFL, indicative of axonal damage, both show promise in reflecting the extent of neuronal injury and predicting recovery outcomes. Additionally, combinations of these biomarkers may enhance diagnostic accuracy and provide more comprehensive insights into the injury mechanisms and prognosis. The use of blood biomarkers in mTBI offers several advantages, including non-invasiveness, rapid turnaround time, and the potential for point-of-care testing. However, challenges such as variability in biomarker levels due to individual differences, the influence of extracranial injuries, and the need for standardized protocols must be addressed. Further research is required to validate these biomarkers in larger, diverse populations and to establish clear clinical guidelines for their use.","og_url":"https:\/\/beyondtheimpact.net\/?p=1892","og_site_name":"Beyond the Impact","article_published_time":"2024-06-22T13:12:39+00:00","article_modified_time":"2025-04-27T10:52:25+00:00","og_image":[{"width":1024,"height":585,"url":"https:\/\/beyondtheimpact.net\/wp-content\/uploads\/2024\/06\/x6pfyknb-1024x585.png","type":"image\/png"}],"author":"Dr Ioannis Mavroudis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Dr Ioannis Mavroudis","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/beyondtheimpact.net\/?p=1892#article","isPartOf":{"@id":"https:\/\/beyondtheimpact.net\/?p=1892"},"author":{"name":"Dr Ioannis Mavroudis","@id":"https:\/\/beyondtheimpact.net\/#\/schema\/person\/1ae68bbf93b4c1d993f388d942a93c4b"},"headline":"Blood biomarkers in mTBI","datePublished":"2024-06-22T13:12:39+00:00","dateModified":"2025-04-27T10:52:25+00:00","mainEntityOfPage":{"@id":"https:\/\/beyondtheimpact.net\/?p=1892"},"wordCount":565,"commentCount":0,"publisher":{"@id":"https:\/\/beyondtheimpact.net\/#organization"},"image":{"@id":"https:\/\/beyondtheimpact.net\/?p=1892#primaryimage"},"thumbnailUrl":"https:\/\/beyondtheimpact.net\/wp-content\/uploads\/2024\/06\/x6pfyknb.png","keywords":["blood biomarkers","GFAP","mTBI","Nf-L","s100b","Tau","UCH-L1"],"articleSection":["Biomarkers","Traumatic brain injury"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/beyondtheimpact.net\/?p=1892#respond"]}]},{"@type":"WebPage","@id":"https:\/\/beyondtheimpact.net\/?p=1892","url":"https:\/\/beyondtheimpact.net\/?p=1892","name":"Blood biomarkers in mTBI - Beyond the Impact","isPartOf":{"@id":"https:\/\/beyondtheimpact.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/beyondtheimpact.net\/?p=1892#primaryimage"},"image":{"@id":"https:\/\/beyondtheimpact.net\/?p=1892#primaryimage"},"thumbnailUrl":"https:\/\/beyondtheimpact.net\/wp-content\/uploads\/2024\/06\/x6pfyknb.png","datePublished":"2024-06-22T13:12:39+00:00","dateModified":"2025-04-27T10:52:25+00:00","breadcrumb":{"@id":"https:\/\/beyondtheimpact.net\/?p=1892#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/beyondtheimpact.net\/?p=1892"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/beyondtheimpact.net\/?p=1892#primaryimage","url":"https:\/\/beyondtheimpact.net\/wp-content\/uploads\/2024\/06\/x6pfyknb.png","contentUrl":"https:\/\/beyondtheimpact.net\/wp-content\/uploads\/2024\/06\/x6pfyknb.png","width":1792,"height":1024},{"@type":"BreadcrumbList","@id":"https:\/\/beyondtheimpact.net\/?p=1892#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/beyondtheimpact.net\/"},{"@type":"ListItem","position":2,"name":"Blood biomarkers in mTBI"}]},{"@type":"WebSite","@id":"https:\/\/beyondtheimpact.net\/#website","url":"https:\/\/beyondtheimpact.net\/","name":"BeyondTheImpact","description":"Concussion, FND and Neuroscience","publisher":{"@id":"https:\/\/beyondtheimpact.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/beyondtheimpact.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/beyondtheimpact.net\/#organization","name":"Beyond the Impact","url":"https:\/\/beyondtheimpact.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/beyondtheimpact.net\/#\/schema\/logo\/image\/","url":"https:\/\/beyondtheimpact.net\/wp-content\/uploads\/2025\/04\/955D378D-9439-4958-AA9D-866B66877DCB-1.png","contentUrl":"https:\/\/beyondtheimpact.net\/wp-content\/uploads\/2025\/04\/955D378D-9439-4958-AA9D-866B66877DCB-1.png","width":1024,"height":1024,"caption":"Beyond the Impact"},"image":{"@id":"https:\/\/beyondtheimpact.net\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/beyondtheimpact.net\/#\/schema\/person\/1ae68bbf93b4c1d993f388d942a93c4b","name":"Dr Ioannis Mavroudis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/beyondtheimpact.net\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/41234bd7f101fbc35534c2cb229c8f7ce061ccbc2ba5bfa19c9dca8b22e28139?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/41234bd7f101fbc35534c2cb229c8f7ce061ccbc2ba5bfa19c9dca8b22e28139?s=96&d=mm&r=g","caption":"Dr Ioannis Mavroudis"},"url":"https:\/\/beyondtheimpact.net\/?author=2"}]}},"_links":{"self":[{"href":"https:\/\/beyondtheimpact.net\/index.php?rest_route=\/wp\/v2\/posts\/1892","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beyondtheimpact.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/beyondtheimpact.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/beyondtheimpact.net\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/beyondtheimpact.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1892"}],"version-history":[{"count":0,"href":"https:\/\/beyondtheimpact.net\/index.php?rest_route=\/wp\/v2\/posts\/1892\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/beyondtheimpact.net\/index.php?rest_route=\/wp\/v2\/media\/1893"}],"wp:attachment":[{"href":"https:\/\/beyondtheimpact.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1892"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/beyondtheimpact.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1892"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/beyondtheimpact.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1892"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}